Long-term disease-free survival of patients with primary cardiac lymphoma treated with systemic chemotherapy and radiotherapy.
10.5045/kjh.2010.45.4.282
- Author:
Dong Yeop SHIN
1
;
Yun Gyoo LEE
;
Hyun Jung LEE
;
Seyoun CHOI
;
Jin Joo PARK
;
Dong Wan KIM
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. kimdw@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Lymphoma;
Myocardial infarction;
Drug therapy;
Radiotherapy
- MeSH:
Antibodies, Monoclonal, Murine-Derived;
Biopsy;
Chest Pain;
Coronary Artery Bypass;
Cyclophosphamide;
Disease-Free Survival;
Doxorubicin;
Humans;
Korea;
Lymphoma;
Lymphoma, B-Cell;
Middle Aged;
Myocardial Infarction;
Prednisolone;
Rare Diseases;
Recurrence;
Transplants;
Vincristine;
Rituximab
- From:Korean Journal of Hematology
2010;45(4):282-285
- CountryRepublic of Korea
- Language:English
-
Abstract:
Primary cardiac lymphoma (PCL) is a rare disease entity with only a few reported cases in Korea. In this paper, we report a case of PCL in a 59-year-old man presenting with chest pain. Diffuse large B-cell lymphoma was diagnosed through a cardiac catheterization-assisted percutaneous endomyocardial biopsy, and there was no evidence of extracardiac involvement of the lymphoma.The patient had a complete clinical response after systemic chemotherapy with a rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen and additional post-chemotherapeutic radiation therapy. The patient experienced a long-term disease-free survival of over 4 years. However, he received coronary artery bypass graft surgery due to an acute myocardial infarction that occurred 3 years after the completion of the radiation therapy. Although the addition of radiation therapy to the treatment is thought to decrease the risk of relapse in patients with PCL, a careful and thorough consideration of the potential complications of radiation therapy, particularly with respect to cardiac complications, should be considered.
